English

10x Genomics, Inc.

EDGAR

TXG Quarterly report (10-Q) · filed 2026-08-07

Annual consolidated revenue for 2025: about USD 642.8M, using the latest reported figures. The previous period, 2024, was about USD 610.8M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

151 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 151036000 USD Source

Operating margin

-12.95%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -19555000 USD Source
Revenue: 151036000 USD Source

Operating cash flow

17 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 43094000 USD Source
Operating Cash Flow: 26120000 USD Source

Free cash flow

15.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 43094000 USD Source
Operating Cash Flow: 26120000 USD Source
Capital Expenditure: 3185000 USD Source
Capital Expenditure: 1597000 USD Source

Cash and cash equivalents: 344 million USD 2024-12-31 Source
Exact value

344067000 USD
Long-term debt including current maturities: 29.7 million USD 2019-12-31 Source
Exact value

29719000 USD
Shares outstanding: 128 million shares 2025-12-31 Source
Exact value

127691329 shares

Reported share-count change

4.42% · 5.4 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

122291837 shares · 2024-12-31· Source
127691329 shares · 2025-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

617 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 149002000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 642823000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 476793000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 150843000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 151036000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-75.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -27472000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -43544000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -27292000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -13470000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -17931000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

127 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 95273000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 52059000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 136050000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 95273000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 26120000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 43094000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 26120000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

5.65 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 4158000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3471000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 5935000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 4158000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1597000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 3185000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1597000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

121 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 95273000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 52059000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 136050000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 95273000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 26120000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: 43094000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 26120000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 4158000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3471000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 5935000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 4158000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1597000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 3185000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1597000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-07.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2019-12-31
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+5.2%

Prior period

USD 610.79 million

2024-01-01 – 2024-12-31
Current period

USD 642.82 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

642823000 − 610785000 = 32038000 USD

610785000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
642823000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Year-over-year change in Revenue: 32038000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 642823000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1628470 Filing: 000162828026007822 Input fundies:Revenue: 610785000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1629445 Filing: 000162828026007822
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 139.08 million

Prior period

−USD 182.63 million

2024-01-01 – 2024-12-31
Current period

−USD 43.54 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-43544000 − -182627000 = 139083000 USD

-182627000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-43544000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Year-over-year change in Net income: 139083000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -43544000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1203000 Filing: 000162828026007822 Input fundies:NetIncome: -182627000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1203771 Filing: 000162828026007822
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+1,941.6%

Prior period

USD 6.66 million

2024-01-01 – 2024-12-31
Current period

USD 136.05 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

136050000 − 6664000 = 129386000 USD

6664000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
136050000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Year-over-year change in Operating cash flow: 129386000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 136050000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1244202 Filing: 000162828026007822 Input fundies:OperatingCashFlow: 6664000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1244855 Filing: 000162828026007822
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-52.1%

Prior period

USD 12.39 million

2024-01-01 – 2024-12-31
Current period

USD 5.94 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

5935000 − 12393000 = -6458000 USD

12393000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
5935000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Year-over-year change in Capital expenditure: -6458000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 5935000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1254977 Filing: 000162828026007822 Input fundies:CapitalExpenditure: 12393000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1255566 Filing: 000162828026007822
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 642.82 million 100% of revenue
Cost of revenue USD 198.94 million 31% of revenue
Operating expenses USD 504.87 million 79% of revenue
Operating income −USD 60.99 million −9.5% of revenue
Tax, interest and other Derived −USD 17.44 million −2.7% of revenue
Net income −USD 43.54 million −6.8% of revenue

Cash

Operating cash flow USD 136.05 million 21% of revenue
Capital expenditure USD 5.94 million 0.9% of revenue
Free cash flow Derived USD 130.12 million 20% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 126% of revenue.
2018 Operating loss: operating costs were 176% of revenue.
2019 Operating loss: operating costs were 112% of revenue.
2020 Operating loss: operating costs were 279% of revenue.
2021 Operating loss: operating costs were 111% of revenue.
2022 Operating loss: operating costs were 133% of revenue.
2023 Operating loss: operating costs were 143% of revenue.
2024 Operating loss: operating costs were 132% of revenue.
2025 Operating loss: operating costs were 109% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	71085000	89460000 Derived	-18375000	387000 Derived	-18762000	-14455000 Derived	Source 2017-01-01 – 2017-12-31: 71085000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -18375000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -18762000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -10699000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 3756000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	146313000	257077000 Derived	-110764000	1721000 Derived	-112485000	-82693000 Derived	Source 2018-01-01 – 2018-12-31: 146313000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -110764000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -112485000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -76409000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 6284000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	245893000	276466000 Derived	-30573000	678000 Derived	-31251000	-8115000 Derived	Source 2019-01-01 – 2019-12-31: 245893000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -30573000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -31251000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 34627000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 42742000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	298845000	832987000 Derived	-534142000	8589000 Derived	-542731000	-254564000 Derived	Source 2020-01-01 – 2020-12-31: 298845000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -534142000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -542731000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -217898000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 36666000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	490490000	542743000 Derived	-52253000	5970000 Derived	-58223000	-122651000 Derived	Source 2021-01-01 – 2021-12-31: 490490000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -52253000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -58223000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -21373000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 101278000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	516409000	684353000 Derived	-167944000	-1944000 Derived	-166000000	-165267000 Derived	Source 2022-01-01 – 2022-12-31: 516409000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -167944000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -166000000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -33606000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 131661000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	618727000	884056000 Derived	-265329000	-10230000 Derived	-255099000	-63798000 Derived	Source 2023-01-01 – 2023-12-31: 618727000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -265329000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -255099000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -15197000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 48601000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	610785000	805344000 Derived	-194559000	-11932000 Derived	-182627000	-5729000 Derived	Source 2024-01-01 – 2024-12-31: 610785000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -194559000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -182627000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 6664000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 12393000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	642823000	703808000 Derived	-60985000	-17441000 Derived	-43544000	130115000 Derived	Source 2025-01-01 – 2025-12-31: 642823000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -60985000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -43544000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 136050000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 5935000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 642.8M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	71085000	Revenue: 71085000 Open source
20182018-12-31	Revenue	146313000	Revenue: 146313000 Open source
20192019-12-31	Revenue	245893000	Revenue: 245893000 Open source
20202020-12-31	Revenue	298845000	Revenue: 298845000 Open source
20212021-12-31	Revenue	490490000	Revenue: 490490000 Open source
20222022-12-31	Revenue	516409000	Revenue: 516409000 Open source
20232023-12-31	Revenue	618727000	Revenue: 618727000 Open source
20242024-12-31	Revenue	610785000	Revenue: 610785000 Open source
20252025-12-31	Revenue	642823000	Revenue: 642823000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

5.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 71085000 Open source
20182018-12-31	Year over year	105.8%	Revenue: 146313000 Open source Revenue: 71085000 Open source
20192019-12-31	Year over year	68.1%	Revenue: 245893000 Open source Revenue: 146313000 Open source
20202020-12-31	Year over year	21.5%	Revenue: 298845000 Open source Revenue: 245893000 Open source
20212021-12-31	Year over year	64.1%	Revenue: 490490000 Open source Revenue: 298845000 Open source
20222022-12-31	Year over year	5.3%	Revenue: 516409000 Open source Revenue: 490490000 Open source
20232023-12-31	Year over year	19.8%	Revenue: 618727000 Open source Revenue: 516409000 Open source
20242024-12-31	Year over year	-1.3%	Revenue: 610785000 Open source Revenue: 618727000 Open source
20252025-12-31	Year over year	5.2%	Revenue: 642823000 Open source Revenue: 610785000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -9.5% 2025

Net margin -6.8% 2025

Free cash flow margin 20.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-25.8%	Operating Income: -18375000 Open source Revenue: 71085000 Open source
20182018-12-31	Operating margin	-75.7%	Operating Income: -110764000 Open source Revenue: 146313000 Open source
20192019-12-31	Operating margin	-12.4%	Operating Income: -30573000 Open source Revenue: 245893000 Open source
20202020-12-31	Operating margin	-178.7%	Operating Income: -534142000 Open source Revenue: 298845000 Open source
20212021-12-31	Operating margin	-10.7%	Operating Income: -52253000 Open source Revenue: 490490000 Open source
20222022-12-31	Operating margin	-32.5%	Operating Income: -167944000 Open source Revenue: 516409000 Open source
20232023-12-31	Operating margin	-42.9%	Operating Income: -265329000 Open source Revenue: 618727000 Open source
20242024-12-31	Operating margin	-31.9%	Operating Income: -194559000 Open source Revenue: 610785000 Open source
20252025-12-31	Operating margin	-9.5%	Operating Income: -60985000 Open source Revenue: 642823000 Open source
20172017-12-31	Net margin	-26.4%	Net Income: -18762000 Open source Revenue: 71085000 Open source
20182018-12-31	Net margin	-76.9%	Net Income: -112485000 Open source Revenue: 146313000 Open source
20192019-12-31	Net margin	-12.7%	Net Income: -31251000 Open source Revenue: 245893000 Open source
20202020-12-31	Net margin	-181.6%	Net Income: -542731000 Open source Revenue: 298845000 Open source
20212021-12-31	Net margin	-11.9%	Net Income: -58223000 Open source Revenue: 490490000 Open source
20222022-12-31	Net margin	-32.1%	Net Income: -166000000 Open source Revenue: 516409000 Open source
20232023-12-31	Net margin	-41.2%	Net Income: -255099000 Open source Revenue: 618727000 Open source
20242024-12-31	Net margin	-29.9%	Net Income: -182627000 Open source Revenue: 610785000 Open source
20252025-12-31	Net margin	-6.8%	Net Income: -43544000 Open source Revenue: 642823000 Open source
20172017-12-31	Free cash flow margin	-20.3%	Revenue: 71085000 Open source Operating Cash Flow: -10699000 Open source Capital Expenditure: 3756000 Open source
20182018-12-31	Free cash flow margin	-56.5%	Revenue: 146313000 Open source Operating Cash Flow: -76409000 Open source Capital Expenditure: 6284000 Open source
20192019-12-31	Free cash flow margin	-3.3%	Revenue: 245893000 Open source Operating Cash Flow: 34627000 Open source Capital Expenditure: 42742000 Open source
20202020-12-31	Free cash flow margin	-85.2%	Revenue: 298845000 Open source Operating Cash Flow: -217898000 Open source Capital Expenditure: 36666000 Open source
20212021-12-31	Free cash flow margin	-25%	Revenue: 490490000 Open source Operating Cash Flow: -21373000 Open source Capital Expenditure: 101278000 Open source
20222022-12-31	Free cash flow margin	-32%	Revenue: 516409000 Open source Operating Cash Flow: -33606000 Open source Capital Expenditure: 131661000 Open source
20232023-12-31	Free cash flow margin	-10.3%	Revenue: 618727000 Open source Operating Cash Flow: -15197000 Open source Capital Expenditure: 48601000 Open source
20242024-12-31	Free cash flow margin	-0.9%	Revenue: 610785000 Open source Operating Cash Flow: 6664000 Open source Capital Expenditure: 12393000 Open source
20252025-12-31	Free cash flow margin	20.2%	Revenue: 642823000 Open source Operating Cash Flow: 136050000 Open source Capital Expenditure: 5935000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 136.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-10699000	Operating Cash Flow: -10699000 Open source
20182018-12-31	Operating cash flow	-76409000	Operating Cash Flow: -76409000 Open source
20192019-12-31	Operating cash flow	34627000	Operating Cash Flow: 34627000 Open source
20202020-12-31	Operating cash flow	-217898000	Operating Cash Flow: -217898000 Open source
20212021-12-31	Operating cash flow	-21373000	Operating Cash Flow: -21373000 Open source
20222022-12-31	Operating cash flow	-33606000	Operating Cash Flow: -33606000 Open source
20232023-12-31	Operating cash flow	-15197000	Operating Cash Flow: -15197000 Open source
20242024-12-31	Operating cash flow	6664000	Operating Cash Flow: 6664000 Open source
20252025-12-31	Operating cash flow	136050000	Operating Cash Flow: 136050000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 130.1M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	-14455000	Operating Cash Flow: -10699000 Open source Capital Expenditure: 3756000 Open source
20182018-12-31	Free cash flow	-82693000	Operating Cash Flow: -76409000 Open source Capital Expenditure: 6284000 Open source
20192019-12-31	Free cash flow	-8115000	Operating Cash Flow: 34627000 Open source Capital Expenditure: 42742000 Open source
20202020-12-31	Free cash flow	-254564000	Operating Cash Flow: -217898000 Open source Capital Expenditure: 36666000 Open source
20212021-12-31	Free cash flow	-122651000	Operating Cash Flow: -21373000 Open source Capital Expenditure: 101278000 Open source
20222022-12-31	Free cash flow	-165267000	Operating Cash Flow: -33606000 Open source Capital Expenditure: 131661000 Open source
20232023-12-31	Free cash flow	-63798000	Operating Cash Flow: -15197000 Open source Capital Expenditure: 48601000 Open source
20242024-12-31	Free cash flow	-5729000	Operating Cash Flow: 6664000 Open source Capital Expenditure: 12393000 Open source
20252025-12-31	Free cash flow	130115000	Operating Cash Flow: 136050000 Open source Capital Expenditure: 5935000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

23.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Liabilities / assets	Not reported	No source recorded
20182018-12-31	Liabilities / assets	81.3%	Total Liabilities: 101053000 Open source Total Assets: 124310000 Open source
20192019-12-31	Liabilities / assets	30.7%	Total Liabilities: 185840000 Open source Total Assets: 605923000 Open source
20202020-12-31	Liabilities / assets	20.5%	Total Liabilities: 190269000 Open source Total Assets: 929341000 Open source
20212021-12-31	Liabilities / assets	19.8%	Total Liabilities: 201258000 Open source Total Assets: 1018826000 Open source
20222022-12-31	Liabilities / assets	21.7%	Total Liabilities: 223237000 Open source Total Assets: 1028980000 Open source
20232023-12-31	Liabilities / assets	23.2%	Total Liabilities: 224100000 Open source Total Assets: 965143000 Open source
20242024-12-31	Liabilities / assets	22.7%	Total Liabilities: 208502000 Open source Total Assets: 918636000 Open source
20252025-12-31	Liabilities / assets	23.5%	Total Liabilities: 245039000 Open source Total Assets: 1041365000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.46× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Current assets / current liabilities	Not reported	No source recorded
20182018-12-31	Current assets / current liabilities	3.28×	Current Assets: 106236000 Open source Current Liabilities: 32362000 Open source
20192019-12-31	Current assets / current liabilities	7.63×	Current Assets: 480840000 Open source Current Liabilities: 63049000 Open source
20202020-12-31	Current assets / current liabilities	6.56×	Current Assets: 774366000 Open source Current Liabilities: 118126000 Open source
20212021-12-31	Current assets / current liabilities	6.77×	Current Assets: 747591000 Open source Current Liabilities: 110357000 Open source
20222022-12-31	Current assets / current liabilities	4.85×	Current Assets: 635035000 Open source Current Liabilities: 130957000 Open source
20232023-12-31	Current assets / current liabilities	4.69×	Current Assets: 596022000 Open source Current Liabilities: 127162000 Open source
20242024-12-31	Current assets / current liabilities	4.97×	Current Assets: 584387000 Open source Current Liabilities: 117633000 Open source
20252025-12-31	Current assets / current liabilities	4.46×	Current Assets: 684451000 Open source Current Liabilities: 153454000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 18.76 million Exact value Exact value: -18762000 USD 2017-01-01 – 2017-12-31: -18762000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2017-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -18762000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18762000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000119312520052640/txg-20191231.xml#190570 Filing: 000119312520052640 The citation records this snapshot. The page link may show a newer release later.	−USD 10.7 million Exact value Exact value: -10699000 USD 2017-01-01 – 2017-12-31: -10699000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2017-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: -10699000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10699000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000119312520052640/txg-20191231.xml#193472 Filing: 000119312520052640 The citation records this snapshot. The page link may show a newer release later.	USD 3.76 million Exact value Exact value: 3756000 USD 2017-01-01 – 2017-12-31: 3756000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2017-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 3756000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3756000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000119312520052640/txg-20191231.xml#193678 Filing: 000119312520052640 The citation records this snapshot. The page link may show a newer release later.	−USD 14.46 million Calculation and evidence -10699000 − 3756000 USD Exact free cash flow: -14455000 USD 2017-01-01 – 2017-12-31: -10699000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 3756000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2017-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -14455000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10699000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000119312520052640/txg-20191231.xml#193472 Filing: 000119312520052640 Input fundies:CapitalExpenditure: 3756000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000119312520052640/txg-20191231.xml#193678 Filing: 000119312520052640 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 112.49 million Exact value Exact value: -112485000 USD 2018-01-01 – 2018-12-31: -112485000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2018-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -112485000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -112485000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000009/txg-20201231.htm#2396143 Filing: 000177078721000009 The citation records this snapshot. The page link may show a newer release later.	−USD 76.41 million Exact value Exact value: -76409000 USD 2018-01-01 – 2018-12-31: -76409000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2018-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: -76409000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76409000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000009/txg-20201231.htm#1523678 Filing: 000177078721000009 The citation records this snapshot. The page link may show a newer release later.	USD 6.28 million Exact value Exact value: 6284000 USD 2018-01-01 – 2018-12-31: 6284000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2018-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 6284000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6284000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000009/txg-20201231.htm#1527560 Filing: 000177078721000009 The citation records this snapshot. The page link may show a newer release later.	−USD 82.69 million Calculation and evidence -76409000 − 6284000 USD Exact free cash flow: -82693000 USD 2018-01-01 – 2018-12-31: -76409000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 6284000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2018-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -82693000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76409000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000009/txg-20201231.htm#1523678 Filing: 000177078721000009 Input fundies:CapitalExpenditure: 6284000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000009/txg-20201231.htm#1527560 Filing: 000177078721000009 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 31.25 million Exact value Exact value: -31251000 USD 2019-01-01 – 2019-12-31: -31251000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2019-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -31251000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31251000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000015/txg-20211231.htm#1402488 Filing: 000177078722000015 The citation records this snapshot. The page link may show a newer release later.	USD 34.63 million Exact value Exact value: 34627000 USD 2019-01-01 – 2019-12-31: 34627000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2019-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: 34627000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 34627000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000015/txg-20211231.htm#1467108 Filing: 000177078722000015 The citation records this snapshot. The page link may show a newer release later.	USD 42.74 million Exact value Exact value: 42742000 USD 2019-01-01 – 2019-12-31: 42742000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2019-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 42742000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 42742000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000015/txg-20211231.htm#1470918 Filing: 000177078722000015 The citation records this snapshot. The page link may show a newer release later.	−USD 8.12 million Calculation and evidence 34627000 − 42742000 USD Exact free cash flow: -8115000 USD 2019-01-01 – 2019-12-31: 34627000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 42742000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2019-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -8115000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 34627000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000015/txg-20211231.htm#1467108 Filing: 000177078722000015 Input fundies:CapitalExpenditure: 42742000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000015/txg-20211231.htm#1470918 Filing: 000177078722000015 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 542.73 million Exact value Exact value: -542731000 USD 2020-01-01 – 2020-12-31: -542731000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2020-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -542731000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -542731000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000012/txg-20221231.htm#1329640 Filing: 000177078723000012 The citation records this snapshot. The page link may show a newer release later.	−USD 217.9 million Exact value Exact value: -217898000 USD 2020-01-01 – 2020-12-31: -217898000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2020-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: -217898000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -217898000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000012/txg-20221231.htm#1394706 Filing: 000177078723000012 The citation records this snapshot. The page link may show a newer release later.	USD 36.67 million Exact value Exact value: 36666000 USD 2020-01-01 – 2020-12-31: 36666000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2020-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 36666000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 36666000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000012/txg-20221231.htm#1401713 Filing: 000177078723000012 The citation records this snapshot. The page link may show a newer release later.	−USD 254.56 million Calculation and evidence -217898000 − 36666000 USD Exact free cash flow: -254564000 USD 2020-01-01 – 2020-12-31: -217898000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 36666000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2020-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -254564000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -217898000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000012/txg-20221231.htm#1394706 Filing: 000177078723000012 Input fundies:CapitalExpenditure: 36666000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000012/txg-20221231.htm#1401713 Filing: 000177078723000012 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 58.22 million Exact value Exact value: -58223000 USD 2021-01-01 – 2021-12-31: -58223000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2021-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -58223000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58223000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000017/txg-20231231.htm#1277295 Filing: 000177078724000017 The citation records this snapshot. The page link may show a newer release later.	−USD 21.37 million Exact value Exact value: -21373000 USD 2021-01-01 – 2021-12-31: -21373000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2021-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: -21373000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21373000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000017/txg-20231231.htm#1314811 Filing: 000177078724000017 The citation records this snapshot. The page link may show a newer release later.	USD 101.28 million Exact value Exact value: 101278000 USD 2021-01-01 – 2021-12-31: 101278000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2021-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 101278000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 101278000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000017/txg-20231231.htm#1321561 Filing: 000177078724000017 The citation records this snapshot. The page link may show a newer release later.	−USD 122.65 million Calculation and evidence -21373000 − 101278000 USD Exact free cash flow: -122651000 USD 2021-01-01 – 2021-12-31: -21373000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 101278000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2021-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -122651000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21373000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000017/txg-20231231.htm#1314811 Filing: 000177078724000017 Input fundies:CapitalExpenditure: 101278000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000017/txg-20231231.htm#1321561 Filing: 000177078724000017 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 166 million Exact value Exact value: -166000000 USD 2022-01-01 – 2022-12-31: -166000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2022-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -166000000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -166000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000013/txg-20241231.htm#1147957 Filing: 000177078725000013 The citation records this snapshot. The page link may show a newer release later.	−USD 33.61 million Exact value Exact value: -33606000 USD 2022-01-01 – 2022-12-31: -33606000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2022-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: -33606000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33606000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000013/txg-20241231.htm#1183719 Filing: 000177078725000013 The citation records this snapshot. The page link may show a newer release later.	USD 131.66 million Exact value Exact value: 131661000 USD 2022-01-01 – 2022-12-31: 131661000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2022-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 131661000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 131661000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000013/txg-20241231.htm#1190475 Filing: 000177078725000013 The citation records this snapshot. The page link may show a newer release later.	−USD 165.27 million Calculation and evidence -33606000 − 131661000 USD Exact free cash flow: -165267000 USD 2022-01-01 – 2022-12-31: -33606000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 131661000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2022-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -165267000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33606000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000013/txg-20241231.htm#1183719 Filing: 000177078725000013 Input fundies:CapitalExpenditure: 131661000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000013/txg-20241231.htm#1190475 Filing: 000177078725000013 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 255.1 million Exact value Exact value: -255099000 USD 2023-01-01 – 2023-12-31: -255099000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2023-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -255099000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -255099000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1204544 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	−USD 15.2 million Exact value Exact value: -15197000 USD 2023-01-01 – 2023-12-31: -15197000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2023-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: -15197000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15197000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1245508 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	USD 48.6 million Exact value Exact value: 48601000 USD 2023-01-01 – 2023-12-31: 48601000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2023-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 48601000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 48601000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1256157 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	−USD 63.8 million Calculation and evidence -15197000 − 48601000 USD Exact free cash flow: -63798000 USD 2023-01-01 – 2023-12-31: -15197000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 48601000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2023-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -63798000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15197000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1245508 Filing: 000162828026007822 Input fundies:CapitalExpenditure: 48601000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1256157 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 182.63 million Exact value Exact value: -182627000 USD 2024-01-01 – 2024-12-31: -182627000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2024-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -182627000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -182627000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1203771 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	USD 6.66 million Exact value Exact value: 6664000 USD 2024-01-01 – 2024-12-31: 6664000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2024-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: 6664000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 6664000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1244855 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	USD 12.39 million Exact value Exact value: 12393000 USD 2024-01-01 – 2024-12-31: 12393000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2024-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 12393000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12393000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1255566 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	−USD 5.73 million Calculation and evidence 6664000 − 12393000 USD Exact free cash flow: -5729000 USD 2024-01-01 – 2024-12-31: 6664000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 12393000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2024-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: -5729000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 6664000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1244855 Filing: 000162828026007822 Input fundies:CapitalExpenditure: 12393000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1255566 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 43.54 million Exact value Exact value: -43544000 USD 2025-01-01 – 2025-12-31: -43544000 USD Inspect Net Income Open source Share or cite Citation for Net Income · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Net Income: -43544000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43544000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1203000 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	USD 136.05 million Exact value Exact value: 136050000 USD 2025-01-01 – 2025-12-31: 136050000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Operating Cash Flow: 136050000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 136050000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1244202 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	USD 5.94 million Exact value Exact value: 5935000 USD 2025-01-01 – 2025-12-31: 5935000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Capital Expenditure: 5935000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5935000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1254977 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.	USD 130.12 million Calculation and evidence 136050000 − 5935000 USD Exact free cash flow: 130115000 USD 2025-01-01 – 2025-12-31: 136050000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 5935000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · 10x Genomics, Inc. · 2025-12-31 10x Genomics, Inc. (edgar:1770787) Free cash flow: 130115000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1770787?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 136050000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1244202 Filing: 000162828026007822 Input fundies:CapitalExpenditure: 5935000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm#1254977 Filing: 000162828026007822 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

36 filings · 2,432 latest values · 2,432 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001770787, 1770787, TXG, edgar:1770787

Also known as 10X Genomics, Inc., 10x Genomics, Inc.

10x Genomics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation